ANZ 100
Alternative Names: ANZ-100; CRS-100Latest Information Update: 18 Aug 2023
At a glance
- Originator Cerus Corporation
- Developer Aduro BioTech
- Class Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Liver cancer